| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892
Phosphodiesterase-4 (PDE4) inhibitors have the potential to modulate immune responses from the Th1 toward the Th2 phenotype and are considered candidate therapies for Th1-mediated autoimmune disorders. However, depending on the model and cell types employed, studies of atopic individuals have come to the opposite conclusion, i.e., that PDE inhibitors may be beneficial in asthma. Using in vitro immunopharmacologic techniques we analyzed the effects of PDE4 and PDE3 inhibitors on human immune cells to address these discrepancies and broaden our understanding of their mechanism of action. Our results indicate that PDE inhibitors have complex inhibitory effects within in vivo achievable concentration ranges on Th1-mediated immunity, whereas Th2-mediated responses are mostly unaffected or enhanced. The Th2 skewing of the developing immune response is explained by the effects of PDE inhibitors on several factors contributing to T cell priming: the cytokine milieu; the type of costimulatory signal, i.e., up-regulation of CD86 and down-regulation of CD80; and the Ag avidity. The combination of PDE4 and PDE3 inhibitors expresses synergistic effects and may broaden the therapeutic window. Finally, we observed a differential sensitivity to PDE inhibition in autoreactive vs foreign Ag-specific T cells and cells derived from multiple sclerosis patients vs those derived from healthy donors. This suggests that PDE inhibition weakens the strength of the T cell stimulus and corrects the underlying disease-associated cytokine skew in T cell-mediated autoimmune disorders. These new findings broaden the understanding of the immunomodulatory actions of PDE inhibitors and underscore their promising drug profile for the treatment of autoimmune disorders.
This article has been cited by other articles:
|
|
 |
|
  B. Bielekova, N. Richert, T. Howard, A. N Packer, G. Blevins, J. Ohayon, H. F McFarland, C.-S. Sturzebecher, and R. Martin Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood--brain barrier disruption in multiple sclerosis Multiple Sclerosis, October 1, 2009; 15(10): 1206 - 1214. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Rossi, D. Padmanaban, J. Ni, L.-A. Yeh, M. A. Glicksman, and H. Waldner Identifying Druglike Inhibitors of Myelin-Reactive T Cells by Phenotypic High-Throughput Screening of a Small-Molecule Library J Biomol Screen, June 1, 2007; 12(4): 481 - 489. [Abstract] [PDF]
|
|
|
|
 |
|
 H. Wang and N. K. Edens mRNA expression and antilipolytic role of phosphodiesterase 4 in rat adipocytes in vitro J. Lipid Res., May 1, 2007; 48(5): 1099 - 1107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Gomes, M. Savignac, M. D. Cabral, P. Paulet, M. Moreau, C. Leclerc, R. Feil, F. Hofmann, J.-C. Guery, G. Dietrich, et al. The cGMP/Protein Kinase G Pathway Contributes to Dihydropyridine-sensitive Calcium Response and Cytokine Production in TH2 Lymphocytes J. Biol. Chem., May 5, 2006; 281(18): 12421 - 12427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Cheng, M. A. Thompson, H. J. Walker, C. E. Gray, M. M. Diaz Encarnacion, G. M. Warner, and J. P. Grande Differential regulation of mesangial cell mitogenesis by cAMP phosphodiesterase isozymes 3 and 4 Am J Physiol Renal Physiol, November 1, 2004; 287(5): F940 - F953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Feng, T. Misu, K. Fujihara, S. Sakoda, Y. Nakatsuji, H. Fukaura, S. Kikuchi, K. Tashiro, A. Suzumura, N. Ishii, et al. Ibudilast, a nonselective phosphodiesterase inhibitor, regulates Th1/Th2 balance and NKT cell subset in multiple sclerosis Multiple Sclerosis, October 1, 2004; 10(5): 494 - 498. [Abstract] [PDF]
|
|
|
|
 |
|
 D. Claveau, S. L. Chen, S. O'Keefe, D. M. Zaller, A. Styhler, S. Liu, Z. Huang, D. W. Nicholson, and J. A. Mancini Preferential Inhibition of T Helper 1, but Not T Helper 2, Cytokines in Vitro by L-826,141 [4-{2-(3,4-Bisdifluromethoxyphenyl)-2-{4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl}-3-methylpyridine-1-oxide], a Potent and Selective Phosphodiesterase 4 Inhibitor J. Pharmacol. Exp. Ther., August 1, 2004; 310(2): 752 - 760. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Giordano, D. M. Magaletti, E. A. Clark, and J. A. Beavo Cyclic Nucleotides Promote Monocyte Differentiation Toward a DC-SIGN+ (CD209) Intermediate Cell and Impair Differentiation into Dendritic Cells J. Immunol., December 15, 2003; 171(12): 6421 - 6430. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Arp, M. G. Kirchhof, M. L. Baroja, S. H. Nazarian, T. A. Chau, C. A. Strathdee, E. H. Ball, and J. Madrenas Regulation of T-Cell Activation by Phosphodiesterase 4B2 Requires Its Dynamic Redistribution during Immunological Synapse Formation Mol. Cell. Biol., November 15, 2003; 23(22): 8042 - 8057. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. C. Heystek, A.-C. Thierry, P. Soulard, and C. Moulon Phosphodiesterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and Th1-polarizing capacity Int. Immunol., July 1, 2003; 15(7): 827 - 835. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Loher, K. Schmall, P. Freytag, N. Landauer, R. Hallwachs, C. Bauer, B. Siegmund, F. Rieder, H.-A. Lehr, M. Dauer, et al. The Specific Type-4 Phosphodiesterase Inhibitor Mesopram Alleviates Experimental Colitis in Mice J. Pharmacol. Exp. Ther., May 1, 2003; 305(2): 549 - 556. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Grader-Beck, A. A. F. L. van Puijenbroek, L. M. Nadler, and V. A. Boussiotis cAMP inhibits both Ras and Rap1 activation in primary human T lymphocytes, but only Ras inhibition correlates with blockade of cell cycle progression Blood, February 1, 2003; 101(3): 998 - 1006. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Zoraghi and T. Seebeck From the Cover: The cAMP-specific phosphodiesterase TbPDE2C is an essential enzyme in bloodstream form Trypanosoma brucei PNAS, April 2, 2002; 99(7): 4343 - 4348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Moon, R. Lee, R. Near, L. Weintraub, S. Wolda, and A. Lerner Inhibition of PDE3B Augments PDE4 Inhibitor-induced Apoptosis in a Subset of Patients with Chronic Lymphocytic Leukemia Clin. Cancer Res., February 1, 2002; 8(2): 589 - 595. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kambayashi, R. P. A. Wallin, and H.-G. Ljunggren cAMP-elevating agents suppress dendritic cell function J. Leukoc. Biol., December 1, 2001; 70(6): 903 - 910. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. SALVI, K. SURESH BABU, and S. T. HOLGATE Is Asthma Really Due to a Polarized T Cell Response Toward a Helper T Cell Type 2 Phenotype? Am. J. Respir. Crit. Care Med., October 15, 2001; 164(8): 1343 - 1346. [Full Text] [PDF]
|
|
|
|
|
|
C. M. Fleming, H. He, A. Ciota, D. Perkins, and P. W. Finn Administration of Pentoxifylline During Allergen Sensitization Dissociates Pulmonary Allergic Inflammation from Airway Hyperresponsiveness J. Immunol., August 1, 2001; 167(3): 1703 - 1711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Zoraghi, S. Kunz, K. Gong, and T. Seebeck Characterization of TbPDE2A, a Novel Cyclic Nucleotide-specific Phosphodiesterase from the Protozoan Parasite Trypanosoma brucei J. Biol. Chem., April 6, 2001; 276(15): 11559 - 11566. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
